Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

NCT06107790 is registered in ClinicalTrials.gov with Zhejiang Hisun Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06107790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06107790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 16, 2018
Completion date
January 28, 2022
Enrollment
570 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer